In the latest quarter, 5 analysts provided ratings for Janux Therapeutics (NASDAQ:JANX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.8, a high estimate of $100.00, and a low estimate of $42.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.69%. Investigating Analy…